专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11897927B2 Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof 有权
公开(公告)号：US11897927B2
公开(公告)日：2024-02-13
申请号：US16348274
申请日：2017-11-30
申请人： Advaxis, Inc.
发明人： Robert Petit , Michael F. Princiotta , Brandon Coder , David Balli
IPC分类号： C07K14/47 , A61K35/74 , A61K39/00 , C12N15/74
CPC分类号： C07K14/4748 , A61K35/74 , A61K39/0011 , A61K39/00115 , A61K39/001103 , A61K39/001104 , A61K39/001107 , A61K39/001157 , A61K39/001186 , A61K39/001188 , A61K39/001189 , A61K39/001194 , A61K39/001195 , C12N15/74 , A61K2039/523 , A61K2039/55544 , A61K2039/55594 , A61K2039/645 , C07K2319/43 , C07K2319/95
摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

2. 发明申请

US20180325964A1 MANUFACTURING DEVICE AND METHOD OF AN IMMUNOTHERAPEUTIC FORMULATION COMPRISING A RECOMBINANT LISTERIA STRAIN 审中-公开
公开(公告)号：US20180325964A1
公开(公告)日：2018-11-15
申请号：US15777480
申请日：2016-11-18
申请人： Advaxis, Inc.
发明人： Anil Eapen , Robert Petit
IPC分类号： A61K35/74 , C12N9/64 , B01D61/18 , B01D61/22 , A61P35/00 , A61K39/00
CPC分类号： A61K35/74 , A61K38/164 , A61K38/177 , A61K39/001194 , A61K2039/522 , A61K2039/523 , A61P35/00 , B01D61/18 , B01D61/22 , B01D65/08 , B01D2311/14 , B01D2311/16 , B01D2311/25 , B01D2313/50 , B01D2315/10 , B01D2315/16 , B01D2321/40 , C07K14/195 , C07K14/71 , C07K2319/00 , C12N9/12 , C12N9/6445 , C12Y206/01021 , C12Y207/10001 , C12Y304/21077 , G01N21/59 , A61K2300/00
摘要： Provided herein are an apparatus and process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria strain comprising a prostate specific antigen (PSA) or a chimeric HER2 antigen fused to a Listeriolysin O (LLO) protein fragment.

3. 发明申请

US20180280487A1 RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF USING THE SAME IN CANCER IMMUNOTHERAPY 审中-公开
公开(公告)号：US20180280487A1
公开(公告)日：2018-10-04
申请号：US15767625
申请日：2016-10-14
申请人： ADVAXIS, INC.
发明人： Robert Petit , Kyle Perry
IPC分类号： A61K39/00 , A61K39/02 , A61K39/39 , A61K39/245 , A61P35/00 , A61K35/74
摘要： The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen.

4. 发明申请

US20170246273A1 RECOMBINANT LISTERIA STRAIN EXPRESSING HETEROLOGOUS ANTIGEN FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：US20170246273A1
公开(公告)日：2017-08-31
申请号：US15325955
申请日：2015-07-17
申请人： Advaxis, Inc. , City of Hope
发明人： Anu Wallecha , Robert Petit , Joshua Ellenhorn , Don J. Diamond
IPC分类号： A61K39/00 , C12N9/90 , A61K39/385 , C12N15/85 , C07K14/195 , C07K14/47
CPC分类号： A61K39/0011 , A61K35/74 , A61K39/385 , A61K2039/522 , A61K2039/523 , A61K2039/572 , A61K2039/6037 , A61P35/00 , C07K14/195 , C07K14/4703 , C07K2319/40 , C07K2319/55 , C12N9/90 , C12N15/85 , C12N2800/107 , C12N2820/55 , C12Y501/01001
摘要： Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.

5. 发明申请

US20190248856A1 Listeria-Based Immunogenic Compositions Comprising Wilms Tumor Protein Antigens And Methods Of Use Thereof 审中-公开
公开(公告)号：US20190248856A1
公开(公告)日：2019-08-15
申请号：US16315082
申请日：2017-06-30
申请人： Advaxis, Inc.
发明人： Michael Princiotta , Robert Petit
IPC分类号： C07K14/47 , C07K14/195 , A61K39/39 , A61K39/00 , A61P35/00
CPC分类号： C07K14/4748 , A61K39/0011 , A61K39/001153 , A61K39/39 , A61K2039/522 , A61K2039/523 , A61K2039/53 , A61K2039/572 , A61P35/00 , C07K14/00 , C07K14/195 , C07K14/4702 , C07K2319/00 , C07K2319/02
摘要： Provided are Listeria-based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or Listeria strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant chimeric polypeptides or fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

6. 发明授权

US10143734B2 Biomarker directed multi-target immunotherapy 有权
公开(公告)号：US10143734B2
公开(公告)日：2018-12-04
申请号：US15119661
申请日：2015-02-18
申请人： Advaxis, Inc.
发明人： Robert Petit
IPC分类号： A61K39/02 , C12Q1/6886 , G01N33/574 , A61K45/06 , A61K39/00 , C07K14/195
摘要： This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a different biomarker, thereby treating said disease in said subject.

7. 发明申请

US20180104284A1 Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof 审中-公开
公开(公告)号：US20180104284A1
公开(公告)日：2018-04-19
申请号：US15573382
申请日：2016-05-12
申请人： Advaxis, Inc.
发明人： Anu Wallecha , Poonam Molli , Robert Petit
IPC分类号： A61K35/74 , A61K39/00 , C07K14/195 , C12N1/36 , C07K16/12
CPC分类号： A61K35/74 , A61K39/0011 , A61K2039/523 , A61K2039/6068 , C07K14/195 , C07K16/1296 , C07K2317/732 , C07K2319/33 , C12N1/36 , C12N9/10 , C12N9/90 , C12N15/74
摘要： The present invention relates to compositions comprising a recombinant attenuated Listeria strain expressing a truncated ActA and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant Listeria strain that expresses a fusion protein of a truncated ActA fused to an antigen.

8. 发明公开

US20230357781A1 LISTERIA-BASED COMPOSITIONS COMPRISING A PEPTIDE MINIGENE EXPRESSION SYSTEM AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：US20230357781A1
公开(公告)日：2023-11-09
申请号：US18316539
申请日：2023-05-12
申请人： Advaxis, Inc.
发明人： Robert Petit , Michael F. Princiotta
IPC分类号： C12N15/74 , A61P35/00 , A61K39/00 , A61K35/74 , C07K14/00 , C12P21/02 , C07K14/195 , C07K14/82
CPC分类号： C12N15/74 , A61P35/00 , A61K39/001106 , A61K35/74 , C07K14/00 , C12P21/02 , C07K14/195 , C07K14/82 , C07K2319/036 , A61K2039/522 , A61K2039/523 , A61K38/00
摘要： This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

9. 发明申请

US20190322714A1 Immunogenic Compositions Targeting Recurrent Cancer Mutations And Methods Of Use Thereof 审中-公开
公开(公告)号：US20190322714A1
公开(公告)日：2019-10-24
申请号：US16348274
申请日：2017-11-30
申请人： Advaxis, Inc.
发明人： Robert Petit , Michael F. Princiotta , Brandon Coder , David Balli
IPC分类号： C07K14/47 , A61K35/74 , A61K39/00 , C12N15/74
摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

10. 发明申请

US20190002891A1 Listeria-Based Compositions Comprising A Peptide Minigene Expression System And Methods Of Use Thereof 审中-公开
公开(公告)号：US20190002891A1
公开(公告)日：2019-01-03
申请号：US15553507
申请日：2016-03-03
申请人： Advaxis, Inc.
发明人： Robert Petit , Michael F. Princiotta
IPC分类号： C12N15/74 , C07K14/195 , C07K14/82 , A61K39/00 , A61P35/00
摘要： This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式